179343-23-8

Basic information

• Product Name: 6-(2,6-dibroMophenyl)pyrido[2,3-d]pyriMidine-2,7-diaMine
• Synonyms: 6-(2,6-dibroMophenyl)pyrido[2,3-d]pyriMidine-2,7-diaMine
• CAS NO: 179343-23-8
• Molecular Formula: C₁₃H₉Br₂N₅
• Molecular Weight: 395.05206
• Mol File: 179343-23-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-(2,6-dibroMophenyl)pyrido[2,3-d]pyriMidine-2,7-diaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2,6-dibroMophenyl)pyrido[2,3-d]pyriMidine-2,7-diaMine(179343-23-8)
• EPA Substance Registry System: 6-(2,6-dibroMophenyl)pyrido[2,3-d]pyriMidine-2,7-diaMine(179343-23-8)

Safety Data

• Hazardous Substances Data: 179343-23-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-(2,6-Dibromophenyl)pyrido[2,3-d]pyrimidine-2,7-diamine is used as a potential therapeutic agent for targeting fibroblast growth factor receptor 1 (FGFR1). Its application is based on the compound's ability to inhibit FGFR1, which is often overexpressed or mutated in various cancers, leading to uncontrolled cell growth and tumor development. By inhibiting FGFR1, 6-(2,6-dibroMophenyl)pyrido[2,3-d]pyriMidine-2,7-diaMine may help in the treatment of cancer and other diseases associated with abnormal FGFR1 activity.
Used in Research and Development:
In addition to its potential therapeutic applications, 6-(2,6-Dibromophenyl)pyrido[2,3-d]pyrimidine-2,7-diamine can be used as a research tool in the development of new drugs targeting FGFR1. It can serve as a lead compound for further optimization and modification to improve its potency, selectivity, and pharmacokinetic properties. 6-(2,6-dibroMophenyl)pyrido[2,3-d]pyriMidine-2,7-diaMine can also be used in various in vitro and in vivo assays to study the role of FGFR1 in cellular processes and disease progression.
Used in Drug Design and Structure-Activity Relationship Studies:
6-(2,6-Dibromophenyl)pyrido[2,3-d]pyrimidine-2,7-diamine can be employed in drug design and structure-activity relationship (SAR) studies to better understand the molecular interactions between the compound and its target protein, FGFR1. By analyzing the compound's structure and its effects on FGFR1 inhibition, researchers can gain insights into the design of more potent and selective FGFR1 inhibitors with improved therapeutic potential.

Upstream product

• 20781-06-0 2,4-diamino-5-pyrimidinecarboxaldehyde 
• 67197-53-9 2-(2,6-dibromophenyl)acetonitrile 

Downstream Products

• 179343-24-9 6-(2,6-dibromo-phenyl)-N²-(3-diethylamino-propyl)-pyrido[2,3-d]pyrimidine-2,7-diamine 

Relevant articles and documents

Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase

A major challenge for new antibiotic discovery is predicting the physicochemical properties that enable small molecules to permeate Gram-negative bacterial membranes. We have applied physicochemical lessons from previous work to redesign and improve the antibacterial potency of pyridopyrimidine inhibitors of biotin carboxylase (BC) by up to 64-fold and 16-fold against Escherichia coli and Pseudomonas aeruginosa, respectively. Antibacterial and enzyme potency assessments in the presence of an outer membrane-permeabilizing agent or in efflux-compromised strains indicate that penetration and efflux properties of many redesigned BC inhibitors could be improved to various extents. Spontaneous resistance to the improved pyridopyrimidine inhibitors in P. aeruginosa occurs at very low frequencies between 10-8 and 10-9. However, resistant isolates had alarmingly high minimum inhibitory concentration shifts (16- to >128-fold) compared to the parent strain. Whole-genome sequencing of resistant isolates revealed that either BC target mutations or efflux pump overexpression can lead to the development of high-level resistance.

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity

In continuing our search for medicinal agents to treat proliferative diseases, we have discovered 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas as a novel class of soluble, potent, broadly active tyrosine kinase (TK) inhibitors. An efficient route

Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGFr, and c-Src tyrosine kinases was developed from compound library screening and lead optimization.' In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biological evaluation, and structure-activity relationships of this series are reported.